- Vienna 2018
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Surface Ablation II
Session Date/Time: Tuesday 08/10/2013 | 16:30-18:00
Paper Time: 17:33
Venue: Main Lecture Hall (Ground Floor)
First Author: : J.Kim SOUTH KOREA
Co Author(s): : I. Song M. Kim H. Tchah C. Choi
Our previous study using rat model showed that intraoperative bevacizumab administration decreased central corneal haze and apoptotic keratocyte number after surface ablation (Invest Ophthalmol Vis Sci. 2012; 53:76457653). We attempt to apply bevacizumab intraoperatively to decrease the postoperative corneal hazy during surface ablation.
Tertiary training hostpital
12 eyes out of 6 patients who underwent surface ablation were included. The eyes were randomly assigned to PRK with intraoperative topical 1.25% bevacizumab (Avastin; Roche Diagnostics, Basel, Switzerland) application and the fellow eye was treated with 0.02% mitomycin C (MMC) application. Immediately after surface ablation, a sponge soaked with bevacizumab or MMC placebo was placed onto each exposed corneal bed in the both eyes. The time length of eye contact with bevacizumab or MMC (10 to 50 seconds) was determined according to the ablation depth. Postoperative information regarding BCVA, UCVA, IOP, refraction, and slit lamp photography was obtained at 7 days and 1 month after surgery.
There were no significant differences between two groups in postoperative BCVA, UCVA, IOP, refraction, and postoperative haze for up to 1 month after surgery.
Bevacizumab can be a safe alternative to MMC during surface ablation to prevent postoperative corneal haze.
Please wait while information is loading.